Hide Notes 

Slide 1: 3rd Workshop Molecular Targets for Cancer 11-12 July 2008, Solstrand Hotel, Bergen Preliminary Programme Friday July 11 Opening Chair Jan van de Loo 08:30-08:40 Rector University Bergen Jan-Willem van de Loo, Directorate F - Health Research, DG RTD, The European Commission 08:40-08:50 Keynote address Rolf Bjerkvig - University of Bergen SESSION 1 - Childhood and adult rare cancers Chair 08:50-10:20 The role of cytogenetics in identifying potentially targetable genetic signatures Paola Dal Cin - Brigham and Women's Hospital, Harvard Medical School, Boston, USA The leukemias - an example of rare diseases Rüdiger Hehlmann - University Hospital Mannheim, University of Heidelberg, Germany Novartis Oncology Pipeline: a wide spectrum of innovative antitumor drugs in development for rare cancers Cristian Massacesi - Medical Director Oncology, Regional Medical Affairs Team, Novartis, Origgio, Italy 10:20-10:50 Coffee Break 10:50-12:50 Targeting the IGF1R in pediatric and adult sarcomas Lee J Helman - Pediatric Oncology, NCI, NIH, Bethesda, USA
Slide 2: Uncommon Cancers in Adults and Children: Pathology, Biology and Genetics of Bone Tumours Pancras Hogendoorn - Leiden University Medical Center, The Netherlands Molecular Targets in Childhood Embryonal Tumors Angelika Eggert – University Hospital Essen, Germany Panel discussion session 1 All speakers sessions 1 12:50-14.10 Lunch SESSION 2 – The tumour microenvironment Chair 14:10-15:40 uPAR as a prognostic biomarker in clinical management Heike Allgayer - German Cancer Research Centre, Heidelberg, Germany Shaping of an efficient adaptive immune microenvironment in human cancer Wolf H Fridman - European Georges Pompidou Hospital, Paris, France Stem cells and leukemia stem cells in AML Claus Nerlov - EMBL Mouse Biology Unit, Monterotondo, Italy 15:40-16:10 Coffee Break 16:10-18:10 Exploiting the convergence of embryonic and tumorigenic signaling pathways to develop new therapeutic targets Mary J Hendrix - Northwestern University, Chicago, USA Pathways connecting inflammation and cancer Alberto Mantovani – Clinical Institute Humanitas, Milan, Italy Title SPEAKER - affiliation, City, Country Panel discussion session 2 All speakers sessions 2 20:00 Dinner and music
Slide 3: Saturday July 12 SESSION 3 - Poor prognosis cancers Chair 8:30-10:30 Glioblastoma pathobiology guides valid treatment targets for invasive tumors Michael E Berens - Translational Genomics Research Institute, Phoenix, USA Non-apoptotic signaling of death-receptors as driving force for malignant progression in pancreatic cancer Holger Kalthoff - University Hospital Schleswig-Holstein, Kiel, Germany Ovarian Cancer – Diagnosis of a Silent Killer Robert Zeillinger - Medical University of Vienna, Austria 10:30-11:00 Coffee Break 11:00-12:30 The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer Eric van Cutsem - University Hospital Gasthuisberg, Leuven, Belgium Mouse intervention models for mesothelioma and lung cancer. Do we hit the target? Anton Berns - Netherlands Cancer Institute, Amsterdam, the Netherlands Title SPEAKER - affiliation, City, Country Panel discussion session 3 All speakers sessions 3 12:30-14:00 Lunch SESSION 4 - Resistance to therapy Chair 14:00-15:30 The CD40 pathway in carcinomas: harnessing signal transduction for tumor therapy Aristides Eliopoulos - University of Crete Medical School, Heraklion, Greece Platinum drug resistance, mechanisms and circumvention in the clinic Lloyd Kelland - University College London, UK
Slide 4: Breast cancer resistance, prognostication and prediction: are we making progress? Per Øystein Lønning - Haukeland University hospital, Bergen, Norway 15:30-16:00 Coffee Break 16:00-17:30 Current status of pharmacogenetics as a basis for patient tailored therapy in oncology Jan H Schellens – Netherlands Cancer Institute, Amsterdam, the Netherlands Title SPEAKER - affiliation, City, Country Panel discussion session 4 All speakers sessions 4 17:30-17:35 Conclusions, wrap-up, adjourn